Kosalaram Goteti

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Christopher Banfield, Matthew Scaramozza, Weidong Zhang et al. · The Journal of Clinical Pharmacology · 2017 · 90 citations · Full text

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced p<i>K</i>_a: Antibacterial Agents with an Improved Safety Profile

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2012 · 88 citations · Full text

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 70 citations · Full text

Met Amplification, Medicine, Pathology +8

Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several Models

Iftekhar Mahmood, Carl‐Michael Staschen, Kosalaram Goteti · The AAPS Journal · 2014 · 50 citations · Full text

Drug Safety, Substance Abuse, Several Models +13

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

Jeremy D. Gale, Steven A. Gilbert, Samuel S. Blumenthal et al. · Kidney International Reports · 2018 · 49 citations · Full text